New hope for lymphoma patients after CAR t fails: glofitamab trial launches
NCT ID NCT07453095
First seen Mar 24, 2026 · Last updated May 08, 2026 · Updated 5 times
Summary
This study tests a drug called glofitamab in 41 people with mantle cell lymphoma whose cancer did not respond or came back after CAR T-cell therapy. The goal is to see if glofitamab can shrink or eliminate tumors. Participants receive the drug and are monitored for response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia
Palermo, Italy
Contact Email: •••••@•••••
Contact
-
A.O.U. Città della Salute e della Scienza - Ematologia Universitaria
Torino, Italy
Contact Email: •••••@•••••
Contact
-
AOU SS. Antonio e Biagio e Cesare Arrigo - SCDU Ematologia
Alessandria, Italy
Contact Email: •••••@•••••
Contact
-
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia
Milan, Italy
Contact Email: •••••@•••••
Contact
-
ASST Spedali Civili - Ematologia
Brescia, Italy
Contact Email: •••••@•••••
Contact
-
Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia
Florence, Italy
Contact Email: •••••@•••••
Contact
-
Azienda Ospedaliera Universitaria Integrata di Verona - U.O. Ematologia
Verona, Italy
Contact Email: •••••@•••••
Contact
-
Azienda Ospedaliera Universitaria Pisana - U.O. Ematologia
Pisa, Italy
Contact Email: •••••@•••••
Contact
-
Grande Ospedale Metropolitano Bianchi Melacrino Morelli - C.T.M.O.
Reggio Calabria, Italy
Contact Email: •••••@•••••
Contact
-
Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia - Ematologia e terapie cellulari
Genova, Italy
Contact Email: •••••@•••••
Contact
-
P.O. Spirito Santo di Pescara - UOC Ematologia Dipartimento Oncologico Ematologico - ASL Pescara
Pescara, Italy
Contact Email: •••••@•••••
Contact
-
Policlinico S.Orsola-Malpighi - Istituto di Ematologia Seragnoli
Bologna, Italy
Contact Email: •••••@•••••
Contact
-
Policlinico Umberto I - Universitа "La Sapienza" - Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione
Roma, Italy
Contact Email: •••••@•••••
Contact
-
ULSS 8 Berica - Ospedale S. Bortolo - Ematologia
Vicenza, Italy
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.